Which targets are you missing when you analyze genetics, 'omics or single-cell data alone?

Focusing on amyotrophic lateral sclerosis (ALS), a complex neuroinflammatory disease with limited therapeutic options and heterogeneous disease biology, we explore how pharma R&D teams can identify high-confidence, developable targets. Instead of focusing on known ALS genes, uncover new targets and disease mechanisms by combining knowledge graphs, multiomics and single-cell data.

See how integrated data analysis can reveal novel, evidence-backed targets – and determine which discoveries are worth pursuing as drug programs.